BY: Jasper Chan
Mar 18, 2022

(Siponimod) Novartis



Available in 0.25 mg film-coated tablets corresponding to 0.25 mg siponimod


Available in 2 mg film-coated tablets corresponding to 2 mg siponimod



For the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity


Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.

The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.